Santen Donates to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan Posted Sep 25, 2018
Santen and Ube Industries Announce Receipt of Manufacturing and Marketing Approval for Glaucoma and Ocular Hypertension Treatment EYBELIS in Japan Posted Sep 21, 2018
Santen Files for Manufacturing and Marketing Approval of Anti-Allergy Ophthalmic Drug Candidate DE-114A (JAN: Epinastine Hydrochloride) Posted Sep 21, 2018
Notice on Completion of Payment for Issuance of New Shares Under Restricted Stock-linked Remuneration Program Posted Jul 26, 2018
Santen Receives Marketing Authorisation from the European Commission for DE-076C (Verkazia) as an Orphan Medicinal Product Posted Jul 10, 2018
Notice on the Issuance of New Shares Under Restricted Stock-Linked Remuneration Program Posted Jun 26, 2018
Notice on the Introduction of a New Stock-Linked Remuneration Program and Change to Director Remuneration Posted May 9, 2018
Santen to Conduct a Public Awareness Campaign for Glaucoma During World Glaucoma Week March 11 - 17 Posted Feb 23, 2018
